MRKR — what changed in the latest 10-Q

Text added vs the prior filing · source: 10-Q · 2026-05-15

• On May 4, 2026, the Company filed a Certificate of Amendment to its Certificate of Incorporation, increasing its authorized shares of Common Stock from 30,000,000 to 130,000,000.

• Operating expenses incurred during the three months ended March 31, 2026 were $4.1 million compared to $5.0 million during the same period ended March 31, 2025. Significant changes and expenditures in operating expenses are outlined as follows:

• Research and development expenses decreased by 9% to $2.8 million for the three months ended March 31, 2026, compared to $3.1 million for the three months ended March 31, 2025.

• The decrease of $0.3 million in 2026 was primarily attributable to a decrease of $0.3 million in stock-based compensation expense due to the modification of certain options in the prior year.

• General and administrative expenses decreased by 10% to $1.2 million for the three months ended March 31, 2026, compared to $1.4 million during the same period ended March 31, 2025.

Text removed vs the prior filing · source: 10-Q · 2025-11-13

• ●Safety – The dose escalation portion of the study tested doses ranging from 100x106-400x106 cells. Infusion of MT-601 was well tolerated in all study participants, with no observation of immune-effector cell associated neurotoxicity syndrome (“ICANS”) and two reported Grade 1 cytokine release syndr…

• ●Efficacy and Duration of Response – Eight out of 12 NHL patients achieved objective responses (66%), with 6 patients demonstrating complete response (“CR”) as best response (50%). Durable responses were observed (range 3-24 months) with 5 NHL patients showing continued response over 6 months, inclu…

• During the three and nine months ended September 30, 2025, we incurred $0.1 million and $1.1 million in expenses related to Cell Ready services and manufacturing costs, respectively (three and nine months ended September 30, 2024 - $1.2 million and $3.1 million, respectively). During the nine months…

• September 30, 2025, we paid approximately $4,000 and $2.7 million related to BCM invoices received, respectively. During the three and nine months ended September 30, 2025, we incurred $0.1 million and $0.3 million, respectively, in expenses related to Cellipont services and manufacturing costs. No …

• On June 16, 2025, Company entered into a Statement of Work (the “SOW”) with Cellipont Bioservices, a leading cell therapy Contract Development and Manufacturing Organization (“CDMO”), for the manufacturing of MT-601, the Company’s lead MAR-T cell product candidate. Pursuant to the SOW, Cellipont wil…

Text added vs the prior filing · source: 10-Q · 2026-05-15

• Director and Officer Trading Plans and Arrangements. During the quarterly period ended March 31, 2026, no director or officer of the Company adopted or terminated any contract, instruction or written plan for the purchase or sale of securities of the Company intended to satisfy the affirmative defen…

Text removed vs the prior filing · source: 10-Q · 2025-11-13

• On August 8, 2025, the Board of Directors of the Company increased Juan Vera’s annual base salary from $400,000 to $440,000. Dr. Vera serves as the Company’s President, Chief Executive Officer and Treasurer.

• Director and Officer Trading Plans and Arrangements. During the quarterly period ended September 30, 2025, no director or officer of the Company adopted or terminated any contract, instruction or written plan for the purchase or sale of securities of the Company intended to satisfy the affirmative d…